Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- RDKK to Enhance Focus on Prediction of Efficacy of Anticancer Drugs
March 30, 2009
- BUSINESS NEWS IN BRIEF
March 30, 2009
- Drugs Eligible for Price Maintenance Must Be Strictly Selected: Chuikyo
March 30, 2009
- FPMAJ Should Maintain Its Stance Regarding Range of Drugs Eligible for Price Maintenance System: Mr Nagano
March 30, 2009
- Industry Proposes to Create Organization to Develop Unapproved Drugs
March 30, 2009
- REGULATORY NEWS IN BRIEF
March 30, 2009
- Dispensing Fees Will Be Cut if Use of Generics Does Not Increase: Mr Urushibata
March 30, 2009
- Guidance for Biosimilars Issued
March 23, 2009
- MEDICAL DEVICE NEWS IN BRIEF
March 23, 2009
- JGA to Improve Its Generics Information Supply System
March 23, 2009
- Why Outsourcing Is the "in" Thing
March 23, 2009
- Savings Notification Services Effective to Promote Use of Generics
March 23, 2009
- Only 30% of Doctors Use Recommended Standard Chemotherapy Regimens
March 23, 2009
- JSGM to Determine Measures to Further Promote Use of Generics
March 23, 2009
- 30% of Asthma Patients Take Oral Steroids: Patient Group Survey
March 23, 2009
- Mr Tsushima Supports NHI Price Maintenance System for New Drugs
March 23, 2009
- 33% of Hospital Pharmacists Write Rx to Change Dosage Form
March 23, 2009
- Materials Derived from Canada-Originated Cow May Be Used without Risk Assessment
March 23, 2009
- Challenges for Pharma Ind. Provide Covance with Unique Opportunity: Mr Barr
March 23, 2009
- REGULATORY NEWS IN BRIEF
March 23, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…